Previous Article | Next Article 
Infect Immun, August 1998, p. 3569-3578, Vol. 66, No. 8
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Pulmonary and Hepatic Gene Expression following
Cecal Ligation and Puncture: Monophosphoryl Lipid A Prophylaxis
Attenuates Sepsis-Induced Cytokine and Chemokine Expression and
Neutrophil Infiltration
Cindy A.
Salkowski,1
Gregory
Detore,1
Alice
Franks,2
Michael C.
Falk,2 and
Stefanie N.
Vogel1 *
Department of Microbiology and Immunology,
Uniformed Services University of the Health Sciences, Bethesda,
Maryland 20814,1 and
Resuscitative
Medicine Program, Naval Medical Research Institute, Bethesda,
Maryland 208892
Received 14 November 1997/Returned for modification 8 January
1998/Accepted 7 May 1998
 |
ABSTRACT |
Polymicrobial sepsis induced by cecal ligation and puncture (CLP)
reproduces many of the pathophysiologic features of septic shock. In
this study, we demonstrate that mRNA for a broad range of pro- and
anti-inflammatory cytokine and chemokine genes are temporally regulated
after CLP in the lung and liver. We also assessed whether prophylactic
administration of monophosphoryl lipid A (MPL), a nontoxic derivative
of lipopolysaccharide (LPS) that induces endotoxin tolerance and
attenuates the sepsis syndrome in mice after CLP, would alter
tissue-specific gene expression post-CLP. Levels of pulmonary
interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-
),
granulocyte colony-stimulating factor (G-CSF), IL-1 receptor antagonist
(IL-1ra), and IL-10 mRNA, as well as hepatic IL-1
, IL-6, gamma
interferon (IFN-
), G-CSF, inducible nitric oxide synthase, and IL-10
mRNA, were reduced in MPL-pretreated mice after CLP compared to control
mice. Chemokine mRNA expression was also profoundly mitigated in
MPL-pretreated mice after CLP. Specifically, levels of pulmonary and
hepatic macrophage inflammatory protein 1
(MIP-1
), MIP-1
,
MIP-2, and monocyte chemoattractant protein-1 (MCP-1) mRNA, as well as
hepatic IFN-
-inducible protein 10 and KC mRNA, were attenuated in
MPL-pretreated mice after CLP. Attenuated levels of IL-6, TNF-
,
MCP-1, MIP-1
, and MIP-2 in serum also were observed in
MPL-pretreated mice after CLP. Diminished pulmonary chemokine mRNA
production was associated with reduced neutrophil margination and
pulmonary myeloperoxidase activity. These data suggest that
prophylactic administration of MPL mitigates the sepsis syndrome by
reducing chemokine production and the recruitment of inflammatory cells
into tissues, thereby attenuating the production of proinflammatory
cytokines.
 |
INTRODUCTION |
The development of sepsis in
surgical, burn, and trauma patients continues to be a substantial cause
of morbidity and the leading cause of mortality in intensive care units
(10). Sepsis-related mortality frequently results from
multiple-organ failure, which is characterized by impaired pulmonary
function (ARDS), hepatic failure, cardiac dysfunction, acute renal
failure, and disseminated intravascular coagulation (10).
During sepsis, neutrophils are sequestered in the lungs and liver
(27, 72) and monocytes are retained in the lungs (17,
59). It is the activation of recruited neutrophils and monocytes,
as well as resident tissue macrophages, and their subsequent
overproduction of proinflammatory mediators that is thought to lead to
the pulmonary and hepatic damage that precedes multiple-organ failure.
Neutrophil sequestration during polymicrobial sepsis and endotoxemia
has been associated with increased chemokine production, augmented
expression of the
2-integrin CD11b/CD18, and
upregulation of selectins such as vascular cell adhesion molecule,
intracellular adhesion molecule, and E-selectin (19, 33, 53, 57,
64). Chemokine production promotes the recruitment of
inflammatory cells, while increased expression of adhesion molecules
facilitates leukocyte-endothelial cell interactions. The importance of
neutrophil-endothelial cell interactions and chemokine production in
the development of lung and liver injury during sepsis and/or
endotoxemia is illustrated by the ability of treatment with Ab to
cellular adhesion molecules and chemokines like MIP-1
and CINC to
attenuate PMN accumulation and tissue damage (19, 20, 33, 53,
57).
MPL is a nontoxic derivative of the lipid A moiety of LPS that was
developed in part as a prophylactic drug for septic shock (44). MPL administration, like pretreatment with sublethal
doses of LPS, induces a state of endotoxin tolerance (30)
such that pretreatment of experimental animals with MPL not only
increases survival rates following shock induced by LPS or TNF-
but
also protects against peritonitis and some infections by gram-negative and -positive bacteria (2, 4, 44). The protective effects of
prophylactic MPL treatment has been associated with attenuated fever,
reduced levels of circulating proinflammatory cytokines (e.g., TNF-
,
IFN-
, IL-6, and IL-8), attenuated development of disseminated
intravascular coagulation, and reduced levels of circulating
transaminases in serum, a measure of liver damage (25, 30, 44,
72). While levels of circulating cytokines have been analyzed in
models of MPL-induced tolerance, whether prophylactic administration of
MPL alters tissue-specific gene expression has yet to be addressed.
Polymicrobial sepsis induced by CLP is a model of sepsis which
reproduces many of the inflammatory and pathological sequelae that are
observed clinically (58, 61). Following CLP, animals develop
bacteremia, hypothermia, hypotension, and damage to multiple organ
systems (1, 43, 60, 61). The lungs develop pathological changes indicative of ARDS, which is fatal. Since the recruitment of
inflammatory cells and overproduction of proinflammatory cytokines mediate the tissue damage leading to multiple-organ failure, we sought
to examine the tissue-specific regulation of chemokine and cytokine
gene expression early after the induction of polymicrobial sepsis. We
also assessed this panel of genes in mice that were given MPL
prophylactically prior to CLP and report that MPL pretreatment reduced
the in vivo expression of the genes encoding a number of
proinflammatory and anti-inflammatory cytokines. Interestingly, the
subset of cytokine mRNAs that was reduced by MPL pretreatment differed
between the lungs and liver, indicating that tolerance can be organ and
gene specific. Moreover, some of the most profound reductions in in
vivo mRNA and protein expression in MPL-pretreated mice after CLP were
observed among the chemokines. Reduced levels of chemokine expression
in MPL-pretreated mice after CLP were associated with reductions in
neutrophil accumulation in the lungs.
 |
MATERIALS AND METHODS |
Abbreviations used in this paper.
Ab, antibody; ARDS, adult
respiratory distress syndrome; CINC, cytokine-induced neutrophil
chemoattractant; CLP, cecal ligation and puncture; CSF,
colony-stimulating factor; ELISA, enzyme-linked immunosorbent assay;
G-CSF, granulocyte-CSF; GM-CSF, granulocyte macrophage-CSF; IFN,
interferon; IL, interleukin; IL-1ra, IL-1 receptor antagonist; iNOS,
inducible nitric oxide synthase; i.p., intraperitoneal; IP-10,
IFN-
-inducible protein 10; LPS, lipopolysaccharide; M-CSF,
macrophage-CSF; MCP, monocyte chemoattractant protein; MIP, macrophage
inflammatory protein; MPL, monophosphoryl lipid A; MPO,
myeloperoxidase; PMN, polymorphonuclear leukocyte; RANTES; SEM,
standard error of the mean; TNF, tumor necrosis factor.
Mice.
C57BL/6J mice (Jackson Laboratories, Bar Harbor,
Maine) were housed in cages with filter tops in a laminar-flow hood and
fed food and acid water ad libitum. Sepsis was induced by CLP. The mice
were anesthetized, and the cecum was ligated below the ileocecal junction; intestinal continuity was maintained. The cecum was punctured
twice with a 20-gauge needle, and a small amount of cecal contents was
expressed through the punctures. The incision was closed, and 1 ml of
sterile saline was administered subcutaneously. By 4 to 6 h after
CLP, all of the mice had developed the early clinical signs of sepsis,
including lethargy, piloerection, and diarrhea. A survival rate of
~90% was observed 24 h after CLP, a mortality rate which was
comparable to that reported for other mouse strains (6, 62).
After CLP, a 90 to 100% mortality rate has been reported, with death
occurring between days 1 to 5 CLP (6, 60, 61, 64). In
tolerance experiments, mice were injected i.p. with 100 µg of MPL
(RIBI ImmunoChemical, Inc., Hamilton, Mont.) or saline 48 h prior
to CLP. This concentration of MPL and timing of MPL pretreatment have
been shown previously by our laboratory and others to reduce the levels
of circulating cytokines and protect against CLP-, LPS-, and
Escherichia coli-mediated death (38, 44). Both
untreated and sham-operated mice served as controls.
The experiments reported herein were conducted according to the
principles set forth in the Guide for the Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources, National Research Council (DHEW Publication NIH 85-23).
ELISAs for cytokine and chemokine levels in serum.
Mice were
bled through the retro-orbital sinus, and the serum was collected and
stored at
70°C. Serum was assayed for IL-6, MCP-1, MIP-1
, MIP-2,
and TNF-
by ELISA as specified by the manufacturer. The lower limits
of sensitivity for the IL-6, MCP-1, MIP-1
, and MIP-2 ELISAs (R & D
Systems, Minneapolis, Minn.) were 3.1, 2, 1.5, and 1.5 pg/ml,
respectively. The lower limit of sensitivity for the TNF-
ELISA
(Genzyme, Cambridge, Mass.) was 15 pg/ml.
Histological testing and MPO assay.
To assess migration of
inflammatory cells into the lungs, histological testing and an MPO
assay were performed. Mice were pretreated with saline or MPL, and
sepsis was induced by CLP, as described above. At 6 h later, one
lung lobe was fixed in phosphate-buffered formalin for histological
evaluation and the remaining lobes were used in the MPO assay. For
histological testing, the lobes were embedded in paraffin, sectioned,
and stained with hematoxylin and eosin. Histopathological changes were
evaluated by the Pathobiology Division, Naval Medical Research
Institute, Bethesda, Md. For the MPO assay, the lobes were washed in
cold saline, blotted dry, weighted, and homogenized in 50 mM sodium
phosphate (pH 6). The homogenate was centrifuged at 35,000 × g (13 min at 4°C), and the supernatant was stored at
70°C. The pellet was resuspended in 0.5%
hexadecyltrimethylammonium bromide in 50 mM sodium phosphate (pH 6),
homogenized on ice with a Polytron homogenizer, freeze-thawed (20 min
at
70°C), and centrifuged at 35,000 × g (13 min at
4°C). The resulting supernatant was frozen at
70°C. MPO activity
was assessed in the supernatant by spectrophotometry with a kinetic computer program. Briefly, test samples were mixed with 2.9 ml of 100 mM potassium phosphate (pH 6) containing 0.17 mg of
o-dianisidine dihydrochloride per ml and 0.0005% hydrogen
peroxide. The change in optical density at 460 nm was measured for 1 to
2 min in a Cary 3 UV/Vis spectrophotometer. Data were derived by linear
regression and are expressed as the optical density at 460 nm per
minute per gram of tissue.
Analysis of tissue mRNA by reverse transcription-PCR.
At the
indicated times after CLP, the liver and lungs were removed from each
animal and frozen at
70°C. The tissues were homogenized in RNA Stat
60 (Tel-Test, Inc., Friendswood, Tex.), and total RNA was isolated as
specified by the manufacturer. Relative quantities of mRNA for each
gene of interest were determined by a coupled reverse transcription-PCR
as described previously (29, 30). The primers (sense [S]
and antisense [AS]) and probe [P] for the chemokines were as
follows: IP-10, 5'-GTGTTGACATCATTGCCACG (S),
5'-GCTTACAGTACAGAGCTAGG (AS), and
5'-GAATCTAAGACCATCAAGAAG (P); KC,
5'-AACGGAGAAAGAAGACAGACTGCT (S),
5'-GACGAGACCAGGAGAAACAGGG (AS), and
5'-GTGAACGCTGGCTTCTGACA (P); MCP-1,
5'-GGAAAAATGGATCCACACCTTGC (S),
5'-TCTCTTCCTCCACCACCATGCAG (AS), and
5'-CTCATTCACCAGCAAGATGA (P); MCP-5,
5'-AGCTTTCATTTCGAAGTCTTTG (S), 5'-CTCCTTATCCAGTATGGTCC (AS), and 5'-CAGTCCTCAGGTATTGGCTGG (P); MIP-1
,
5'-CCCAGCCAGGTGTCATTTTCC (S), 5'-GCATTCAGTTCCAGGTCAGTG
(AS), and 5'-TGCGCTGACTCCAAAGAGAC (P); MIP-1
,
5'-CCCTCTCTCTCCTCTTGCTCGT (S),
5'-TTCAACTCCAAGTCACTCATGTACTCA (AS), and
5'-AAAGAGGCAGACAGATCTGTGCTAAC (P); MIP-2,
5'-TGGGTGGGATGTAGCTAGTTCC (S),
5'-AGTTTGCCTTGACCCTGAAGCC (AS), and
5'-CCTGATGTGCCTCGCTGTCTG (P); and RANTES,
5'-GCGGGTACCATGAAGATCTCTG (S),
5'-CACTTCTTCTCTGGGTTGGCAC (AS), and
5'-GCAGTCGTGTTTGTCACTCGAA (P). The primers and probes for
all other genes assessed in this study have been published previously
(22, 23, 42, 52, 70). The optimum number of cycles for each
organ and gene was determined empirically and was defined as the number
of cycles that resulted in detectable PCR-amplified product under
nonsaturating conditions.
Detection and quantitation of PCR products.
Amplified
products were electrophoresed and transferred to Hybond N+
membranes (Amersham, Arlington Heights, Ill.) in 10× SSC (1× SSC is
0.15 M NaCl plus 0.015 M sodium citrate) by standard southern blotting
techniques. DNA was cross-linked by exposure to UV light, baked onto
the nylon membrane, and hybridized with an internal oligonucleotide
probe. Labeling of the probe and subsequent detection of bound probe
were carried out with an enhanced chemiluminescence system (Amersham).
Chemiluminescent signals were quantified with a scanner (Datacopy GS
plus; Xerox Imaging Systems, Sunnyvale, Calif.). To determine the
magnitude of change in gene expression, cDNA from a sample known to be
positive for the transcript of interest was used to generate a standard
curve by serial dilution of the positive control and simultaneous
amplification. The signal of each band was plotted and fit to a
standard curve by linear regression. The equation from this line was
used to calculate the relative expression levels in test samples. Data
were individually normalized for the relative quantity of mRNA by
comparison to hypoxanthine-guanine phosphoribosyltransferase. Mean fold
changes and SEM were calculated from the signal obtained from at least six mice analyzed at each time point. For each organ, means are expressed as fold induction relative to the response of untreated controls (t = 0), which was arbitrarily assigned a
value of 1; this precludes the comparison of basal gene expression
between organs.
Statistics.
Results were analyzed by Student's t
test for comparisons between two groups. P < 0.05 were
accepted as the level of significance. All experiments were repeated
two or three times with similar results.
 |
RESULTS |
Kinetic analysis of proinflammatory cytokine and iNOS mRNA
expression.
Peak levels of circulating cytokines like TNF-
and
IL-6 can be detected during the first few hours after CLP
(62). It is the overproduction of these and other
proinflammatory cytokines that leads to the tissue damage observed
during polymicrobial sepsis. Both severe ARDS (61) and
hepatic injury (60) have been found by 24 h after CLP.
Thus, in initial experiments, we established the kinetics of pulmonary
and hepatic mRNA expression for the cytokines IL-1
, IL-6, TNF-
,
IFN-
, IL-12 (p35 and p40), G-CSF, M-CSF, and GM-CSF at 1, 3, 6, and
18 h after CLP. As shown in Fig. 1A,
IL-1
, IL-6, TNF-
, and IFN-
mRNA levels in the lungs were
increased over those in sham-operated controls by 3 h after CLP
and remained heightened for 18 h. In contrast to the slightly slower gene induction observed in the lungs, substantial increases in
IL-1
, IL-6, and TNF-
mRNA levels in the liver, compared with those in sham-operated controls, were observed by 1 h after CLP (Fig. 1B). Even 18 h after CLP, IL-1
, IL-6, and TNF-
mRNA
expression in the liver remained heightened over that in sham-operated
controls. IFN-
mRNA was not induced in the liver until 6 h
after CLP, and its level remained elevated at 18 h. In contrast to
IL-12 p35 mRNA in the lungs, which was weakly modulated (
twofold),
IL-12 p35 mRNA in the liver was induced ~10-fold at 6 and 18 h
after CLP. Interestingly, levels of IL-12 p40 mRNA in both the lungs and liver were poorly modulated following CLP, with some mice failing
to respond with increased IL-12 p40 mRNA expression.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 1.
Regulation of proinflammatory cytokine mRNA expression
in the lungs (A) and liver (B) following CLP. Data are expressed as the
mean ± SEM from at least six individual mice. Means are expressed
relative to the response of untreated mice (t = 0),
which was arbitrarily assigned a value of 1. Sham-operated mice served
as controls. When not visible, SEM bars are smaller than the symbol.
|
|
Hypotension develops after CLP and the ensuing bacteremia. Recently,
iNOS knockout mice were used to demonstrate an iNOS-independent pathway
of LPS-induced hypotension (37). Increased levels of iNOS
mRNA in the lungs and liver, compared with those in sham-operated controls, were not observed until 3 h after CLP and peaked by 6 h after CLP (Fig. 2). A more
dramatic increase in the level of iNOS mRNA was observed in the liver
(>200-fold) than in the lungs (~7-fold). While iNOS mRNA expression
in the lungs had declined to near basal levels by 18 h, the level
in the liver remained elevated (~15-fold) over that in sham-operated
controls.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 2.
Modulation of iNOS mRNA expression in the lungs and
liver following CLP. Data were obtained as described in the legend to
Fig. 1.
|
|
While pretreatment with G-CSF or GM-CSF protects against death in
rodent models of peritonitis (5, 41), whether CSF mRNA expression is modulated during polymicrobial sepsis has not been addressed. G-CSF mRNA was strongly induced (
10-fold) by 3 h in both the lungs and liver and remained at heightened levels 18 h
after CLP (Fig. 3). In striking contrast
to G-CSF mRNA, only a slight increase in M-CSF and GM-CSF mRNA (between
two- and fourfold) were observed in the liver and lungs following CLP.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 3.
Temporal regulation of G-CSF ( ), M-CSF ( ), and
GM-CSF ( ) mRNA expression in the lungs and liver following CLP. CSF
mRNA expression was not modulated in sham-operated mice control mice
(data not shown). Data were obtained as described in the legend to Fig.
1.
|
|
Regulation of anti-inflammatory cytokine mRNA expression during
sepsis.
IL-10 and IL-1ra protect against CLP-mediated death and/or
sepsis (1, 34, 58). Recently, IL-11 was shown to
down-regulate the expression of many LPS-induced cytokines, including
TNF-
, IL-1
, and IFN-
, in vivo (55). Therefore, we
next examined the temporal expression of potential negative regulators
of the proinflammatory cytokine cascade that is induced during sepsis. IL-1ra mRNA was induced by 1 h in the lungs after CLP and by
3 h in the liver after CLP (Fig. 4).
The peak IL-1ra mRNA level (~10-fold increase) occurred 3 to 6 h
after CLP and was sustained for 18 h. IL-10 mRNA in the lungs was
induced by 3 h after CLP, while the IL-10 mRNA level in the liver
was increased over that in sham-operated controls by 1 h.
Interestingly, the IL-10 mRNA level in the lungs continued to increase,
while the level in the liver slowly declined by 18 h. IL-11 mRNA
expression in the lungs and liver was not modulated during sepsis (data
not shown).

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 4.
Regulation of anti-inflammatory cytokine mRNA expression
following CLP. Data were obtained as described in the legend to Fig.
1.
|
|
Temporal analysis of chemokine mRNA expression during sepsis.
During sepsis, neutrophils and monocytes accumulate in the lungs and
liver (17, 27, 59, 72). To address the role of chemoattractant production in mediating the influx of inflammatory cells, chemokine mRNA induction during polymicrobial sepsis was next
investigated. As shown in Fig. 5A,
MIP-1
, MIP-1
, MIP-2, and IP-10 mRNA levels in the lungs were
strongly induced by 1 to 3 h after CLP, peaking at ~10- to
100-fold-higher levels than those observed in sham-operated controls 3 to 6 h after CLP. mRNA expression remained heightened (~10-fold)
over that in sham-operated controls 18 h after CLP. In contrast,
MCP-1 and KC mRNA levels in the lungs peaked (~10-fold) at 3 h
after CLP and declined to basal levels by 18 h. MCP-5 and RANTES
mRNA levels in the lungs were poorly modulated (<two- to threefold)
over those in sham-operated controls during sepsis.

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 5.
Temporal regulation of chemokine mRNA expression in the
lungs and liver following CLP ( ) or sham operation ( ). Data were
obtained as described in the legend to Fig. 1.
|
|
A slightly different pattern of chemokine mRNA expression was observed
in the liver. Not only MIP-1
, MIP-1
, and MIP-2 mRNA, but also
MCP-1 and KC mRNA, were strongly induced (~10- to 100-fold) during
sepsis (Fig. 5B). Moreover, the subset of chemokine mRNA levels that
remained heightened in the liver 18 h after CLP differed. Specifically, MIP-1
, MCP-1, and KC mRNA levels, but not MIP-1
or
MIP-2 mRNA levels, remained heightened (~5- to 20-fold) 18 h
after CLP. Finally, IP-10, MCP-5, and RANTES mRNA levels in the liver
were increased later (6 h) and to a much lower extent than for the
other chemokine mRNAs in the liver. By 18 h after CLP, IP-10,
MCP-5, and RANTES mRNA levels approached those exhibited by controls.
MPL pretreatment reduces cytokine, iNOS, and chemokine mRNA
expression during sepsis.
We and others have demonstrated that
pretreatment with MPL induces endotoxin tolerance in vivo, reducing the
levels of circulating cytokines like TNF-
, IFN-
, and IL-6
following LPS challenge, as well as protecting against CLP-, LPS-, and
E. coli-mediated death (4, 30, 38, 44). Thus, we
next examined whether MPL-induced tolerance modulated proinflammatory
cytokine, anti-inflammatory cytokine, and chemokine mRNA expression in
the lungs and liver during polymicrobial sepsis. Mice were pretreated
with 100 µg of MPL or saline 48 h prior to either CLP or sham
operation, and the levels of cytokine and chemokine mRNA were assessed
6 h later. Only genes which had been modulated >twofold during
CLP (Fig. 1 to 5) were examined in the tolerance experiments. G-CSF,
IL-6, TNF-
, IL-1ra, and IL-10 mRNA levels in the lungs were reduced 46 to 78% in MPL-pretreated mice after CLP compared to those in saline-pretreated mice after CLP (Fig.
6A). G-CSF, IL-1
, IL-6, TNF-
,
IFN-
, iNOS, and IL-10 mRNA levels in the liver were reduced 45 to
95% in MPL-pretreated mice after CLP compared to those in saline-pretreated mice after CLP (Fig. 6B). Interestingly, IL-1
, IFN-
, and iNOS mRNA levels in the lungs and the IL-1ra mRNA level in
the liver were not down-regulated in MPL-pretreated mice after CLP.
Finally, the level of mRNA for the anti-inflammatory cytokine IL-11 was
not modulated in MPL-pretreated mice after CLP (data not shown).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 6.
Effect of MPL-pretreatment on cytokine and iNOS mRNA
expression in the lungs (A) and liver (B) during sepsis. Mice were
injected i.p. with either saline or MPL (100 µg) 48 h prior to
CLP or sham operation. The lungs and liver were removed 6 h after
CLP. Data are expressed as the mean ± SEM from six individual
mice and are expressed relative to the response of untreated mice (data
not shown), which were arbitrarily assigned a value of 1. When not
visible, SEM bars are smaller than the symbol. Data in parentheses are
the fold decrease in mRNA expression observed in MPL-pretreated
(tolerized) mice after CLP compared to saline-pretreated (nontolerized)
mice after CLP.
|
|
The tolerizing effect of MPL on CLP-induced chemokine gene expression
was even more profound (Fig. 7). In the
lungs, MIP-1
, MIP-1
, MIP-2, and MCP-1 mRNA levels were reduced 49 to 91% in MPL-pretreated mice after CLP. Moreover, in the liver,
MIP-1
, MIP-1
, MIP-2, IP-10, and MCP-1 levels were reduced 78 to
95% in MPL-pretreated mice after CLP compared to those in
saline-pretreated mice after CLP. Interestingly, expression of a subset
of chemokine genes that included IP-10 mRNA in the lungs and KC, MCP-5,
and RANTES mRNA in the liver (Fig. 7 and data not shown) was not
reduced in MPL-pretreated mice after CLP.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 7.
MPL pretreatment reduces chemokine mRNA expression in
the lungs (A) and liver (B) during sepsis. Data were obtained as
described in the legend to Fig. 6.
|
|
MPL pretreatment reduces the levels of circulating cytokines and
chemokines during CLP-induced sepsis.
We next assessed whether
reduced levels of mRNA expression in the tissues of MPL-pretreated mice
after CLP were associated with a corresponding decrease in circulating
cytokine and/or chemokine levels. Levels of IL-6, TNF-
, MCP-1,
MIP-1
, and MIP-2 in serum were quantified by ELISA from the same
mice assessed for mRNA expression in Fig. 6 and 7. As shown in Table
1, MPL-pretreated mice had substantially
reduced levels (
fivefold) of IL-6, TNF-
, MCP-1, MIP-1
, and
MIP-2 in serum after CLP than did saline-pretreated mice after CLP.
Neutrophil margination and MPO activity are reduced during
MPL-induced tolerance.
Since MPL-pretreated mice exhibited
substantially lower levels of chemokine mRNA in their lungs, as well as
reduced levels of circulating chemokines, after CLP than did
saline-pretreated mice, histopathological changes and MPO activity in
the lungs were assessed in saline- and MPL-pretreated mice 6 h
after CLP. Normal lung tissue was observed in both saline- and
MPL-pretreated sham-operated control mice. Increased neutrophil
margination along pulmonary venules was observed in four of five
saline-pretreated mice and only in two of five MPL-pretreated mice.
Moreover, MPO activity, which has been used as a more sensitive,
quantitative measure of neutrophil sequestration (27, 66),
was reduced (~threefold [P = 0.002]) in the lungs
of MPL-pretreated mice after CLP compared to that in saline-pretreated
mice after CLP (Table 2).
 |
DISCUSSION |
In the present study, we addressed the in vivo kinetics of a large
panel of proinflammatory and anti-inflammatory cytokines, as well as
chemokines, in the lungs and liver following CLP. This allowed us, as
sepsis progressed, to monitor gene expression in two organ systems that
are typically involved in the multiple-organ dysfunction syndrome
observed clinically. The genes used in this study were chosen for their
potential involvement as mediators of the overwhelming inflammatory
response and the resulting pathological sequelae observed during
sepsis. To date, mRNA expression following CLP had been monitored for
only a few genes, including those encoding TNF-
, IL-1
, iNOS,
IL-10, and CINC (a rat analog of KC) (15, 26, 35, 58, 67).
Our data demonstrate that IL-1
, TNF-
, IL-6, and iNOS mRNAs are
strongly induced following CLP, with generally greater increases and
faster kinetics in the liver than in the lungs. A striking observation
was the profound increase in TNF-
mRNA expression observed in the
liver after CLP. This was unexpected since the high levels of
circulating TNF-
observed during endotoxemia in mice (26, 45,
48) are not typically observed after CLP (Table 1) (26,
27). Moreover, only modest increases in TNF-
mRNA expression
in tissues have been observed after LPS challenge (48, 56).
This discordance between tissue-specific TNF-
mRNA production and
protein levels in serum between models of endotoxicity and sepsis
suggests that locally synthesized TNF-
does not necessarily reach
the circulation and that the levels of a particular cytokine in serum
are not always an accurate reflection of events in the tissue
microenvironment (48). Moreover, the data also suggest
fundamental differences between LPS and CLP with regard to TNF
induction. This is supported by the observation that anti-TNF Abs
protect against death during endotoxicity but not during polymicrobial
sepsis induced by CLP (8, 18).
IFN-
enhances both the CLP- and LPS-induced mortality rate (28,
39). In many systems, including endotoxicity, IL-12 appears to be
both proximal to and required for IFN-
production (29, 71). While IFN-
mRNA expression was induced in both the lungs and liver following CLP, IL-12 p40 mRNA levels in the lungs and liver
and IL-12 p35 mRNA levels in the lungs were only weakly modulated. The
IL-12 p40 mRNA data obtained in the CLP model are in sharp contrast to
the profound induction of hepatic IL-12 p40 mRNA (>100-fold) observed
after LPS challenge (48) and suggest that IL-12 may not
contribute to the induction of IFN-
in the CLP model to the same
extent as has been observed in LPS-injected mice. Recently, IL-18 also
has been demonstrated to up-regulate IFN-
and anti-IL-18 Ab
prevented liver damage in Proprionibacterium acnes-sensitized, LPS-challenged mice (40). Whether
IL-18 is involved in up-regulating IFN-
production during sepsis is
unknown. Of note, IL-12 p35 mRNA was induced ~10-fold in the liver
after CLP, as observed after LPS injection (48); typically,
IL-12 p40 mRNA production exceeds that of IL-12 p35 (13, 29,
48). While excess IL-12 p40 is secreted and functions as a
receptor antagonist (36), IL-12 p35 secretion has not been
observed (14).
The CSFs are a family of growth factors that promote the proliferation
and differentiation of myeloid precursors and the activation of
neutrophils and monocytes. G-CSF, GM-CSF, and M-CSF enhance chemotaxis
and phagocytosis and upregulate
2-integrin and selectin expression on phagocytic and endothelial cells (12, 24, 50, 65). While pretreatment with G-CSF or GM-CSF protects against death in rodent models of peritonitis (5, 41), whether CSF mRNA expression was modulated during sepsis was previously unknown. We
observed a striking increase in G-CSF mRNA levels in both the lungs and
liver and a modest increase in the M-CSF mRNA level in the lungs
following CLP. In contrast, the M-CSF mRNA level in the liver and the
GM-CSF mRNA levels in the lungs and liver were weakly induced. During
endotoxemia, large increases in G-CSF, GM-CSF, and M-CSF mRNA levels in
the liver (20- to 100-fold) are observed (48, 49), once
again illustrating that substantial differences in tissue-specific gene
induction are observed between models of polymicrobial sepsis and
endotoxemia.
IL-10 is a potent inhibitor of LPS-induced gene transcription,
down-regulating a broad range of cytokines and chemokines (7, 16,
46), and endogenous production of IL-10 during sepsis is
protective (58, 63). In this study, IL-10 mRNA was induced rapidly in the liver but its induction in the lungs was delayed. These
data are in agreement with IL-10 mRNA data published by van der Poll et
al. (58). More recently, IL-11 was shown to inhibit TNF-
,
IL-1
, and IFN-
in serum following LPS injection (55).
In contrast to IL-10, we observed no in vivo modulation of IL-11 mRNA
after CLP, indicating that while IL-11 has efficacy in down-regulating
LPS-induced cytokines, it may not be endogenously produced during
septic shock.
Disrupting the recruitment of inflammatory cells with Abs to either
PMNs, MIP-1
, or MIP-2 attenuates tissue damage during endotoxemia
and peritonitis (32, 51, 53, 66), and illustrates the
importance of chemokine production and inflammatory cell recruitment in
the pathological findings associated with sepsis. A diverse array of
chemokines were induced in the lungs and liver during polymicrobial
sepsis. The most profound up-regulation (>150-fold) of chemokine mRNA
expression was observed for PMN chemoattractants, i.e., MIP-2 in the
lungs and KC in the liver. These data support and extend the work of
others, who found MIP-2 in serum and organ homogenates and both CINC/KC
mRNA and protein in the liver (15, 64). Recently, anti-MIP-2
Ab was shown to reduce only partially the number of infiltrating
neutrophils in peritoneal fluid after CLP (64). The results
of this study, in combination with our in vivo data, suggest that other
PMN chemoattractants, like KC, which has roughly equivalent potency to
MIP-2 (69), and G-CSF, which also has chemotactic activity
(12), and possibly others, contribute to PMN recruitment
during sepsis. Large increases in the levels of monocyte
chemoattractants were also observed after CLP. In the liver, MCP-1,
MIP-1
, and MIP-1
mRNA levels were up-regulated ~80-, 35-, and
30-fold, respectively, while production of MIP-1
, MIP-1
, and
IP-10 predominated in the lungs. In vitro, MCP-1 is a potent monocyte
chemoattractant with an activity comparable to that of IL-8 activity
for PMNs, while MIP-1
and MIP-1
are progressively less potent
than MCP-1 (11).
In the lungs, increased PMN infiltration precedes increased macrophage
numbers after LPS injection (53, 59), and an analogous situation presumably occurs after CLP. However, no overt differences in
the kinetics of PMN and monocyte chemoattractants in either the lungs
or the liver were observed. In the lungs, for example, MIP-1
, IP-10,
and MIP-2 were induced 1 h after CLP, indicating that both
monocyte and PMN recruitment begins quite early. Finally, of all the
chemokines examined, only pulmonary MCP-5 and RANTES were poorly
modulated (<threefold). Of interest, these chemokines were
up-regulated to a greater extent in the lungs following LPS challenge
(47).
Prophylactic administration of MPL protects against CLP-, E. coli-, and LPS-mediated death and is associated with ameliorated production of circulating cytokines and attenuated liver damage (2, 4, 25, 30, 38, 44). These studies demonstrate for the
first time that MPL pretreatment profoundly alters tissue-specific mRNA
expression in tissues that are associated with organ failure. The
levels of tissue mRNA and/or serum protein for proinflammatory mediators like TNF-
, IL-1
, IL-6, IFN-
, and iNOS were reduced, and in some cases ablated, in MPL-pretreated mice after CLP. These agents mediate the adhesive properties of phagocytic cells, vascular dysfunction, tissue damage and/or potentiate death during sepsis (9, 21, 35, 39, 54, 68). Noteworthy was the tissue-specific difference in genes that were rendered tolerant by MPL pretreatment. Specifically, IL-1
, IFN-
, and iNOS mRNA levels in the liver, but
not the lungs, were reduced in MPL-pretreated mice after CLP. Anti-inflammatory cytokine (IL-10 and IL-1ra) levels also were reduced
in MPL-pretreated mice after CLP. This would suggest that reduced
levels of proinflammatory mediators observed in tolerized subjects
rendered septic are not likely to be due to the overproduction of
anti-inflammatory cytokines with broad negative regulatory activity,
such as IL-10 and IL-11.
In these studies, we observed profound reductions in chemokine mRNA
production in the lungs and liver of MPL-pretreated mice after CLP, as
well as in their serum. While not all the chemokine genes examined were
affected, a broad range of neutrophil and monocyte chemoattractants
showed reduced levels. Moreover, reduction in the chemokine mRNA level
corresponded to decreased leukocyte margination and MPO activity in the
lungs, indicating that endotoxin tolerance attenuates neutrophil
accumulation in vivo. These findings support and extend the work by Yao
et al. (72), who demonstrated reduced MPO activity in the
lungs, liver, kidneys, and heart of MPL-pretreated rats challenged with
LPS. In toto, these data suggest that prophylactic administration of
MPL attenuates chemokine production, thereby reducing the number of
inflammatory cells migrating into tissue. This is concomitant with a
reduced production of proinflammatory mediators in tissues, attenuating
organ damage and increasing survival. The reduced level of
proinflammatory mediators in a particular organ is probably due to not
only decreased numbers of activated recruited cells but also reduced
cytokine production by both resident and recruited cells. To this end,
macrophages (cells central to the host response to LPS
[48]) that have been tolerized with MPL prior to LPS
treatment have suppressed levels of TNF
, IL-1
, and IP-10
(31). Finally, the IL-8 level in serum is decreased in human
volunteers prophylactically administered MPL prior to LPS challenge
(3).
In summary, we have demonstrated that mRNA expression for a broad range
of proinflammatory and anti-inflammatory cytokines and chemokines is
up-regulated during the course of polymicrobial sepsis. In general,
cytokine and chemokine mRNA expression was induced earlier in the liver
than in the lungs. Prophylactic administration of MPL reduced the level
of tissue-specific mRNA for a number of cytokines and chemokines. A
concomitant diminution of cytokine and chemokine protein levels was
observed in the serum. Attenuated levels of chemokine expression were
associated with reductions in pulmonary neutrophil accumulation. The
ability of prophylactic MPL treatment to mitigate the recruitment of
inflammatory cells into organs during the course of an inflammatory
event like sepsis under the conditions used in this study, along with
the concomitant reduction in the levels of proinflammatory mediators,
very probably contributes to the capacity of MPL to ameliorate tissue
damage (25) and to provide nonspecific resistance to a
diverse array of agents including TNF-
, gram-positive and negative
bacteria and their products, and other infectious agents
(44).
 |
ACKNOWLEDGMENTS |
We thank J. Terry Ulrich, RIBI ImmunoChemical Research, Inc., for
providing the MPL used in these studies, and we thank Diana Miller for
technical assistance.
This work was supported by NMRDC protocol
63706NM0095.001.9401 and NIH grant AI-18797 (to S.N.V.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, Uniformed Services University of the
Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD 20814. Phone:
(301) 295-3446. Fax: (301) 295-1545. E-mail: vogel{at}usuhsb.usuhs.mil.
Editor: J. R. McGhee
 |
REFERENCES |
| 1.
|
Alexander, H. R.,
G. M. Doherty,
D. J. Venzon,
M. J. Merino,
D. L. Fraker, and J. A. Norton.
1992.
Recombinant interleukin-1 receptor antagonist (IL-1ra): effective therapy against Gram-negative sepsis in rats.
Surgery
112:188-194[Medline].
|
| 2.
|
Astiz, M. E.,
A. Galera,
D. C. Saha,
C. Carpati, and E. C. Rackow.
1994.
Monophosphoryl lipid A protects against gram-positive sepsis and tumor necrosis factor.
Shock
2:271-274[Medline].
|
| 3.
|
Astiz, M. E.,
E. C. Rackow,
J. G. Still,
S. T. Howell,
A. Cato,
K. B. Von Eschen,
J. T. Ulrich,
J. A. Rudbach,
G. McMahon,
R. Vargas, and W. Stern.
1995.
Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: a prospective, double-blind, randomized, controlled trial.
Crit. Care Med.
23:9-17[Medline].
|
| 4.
|
Astiz, M. E.,
D. C. Saha,
C. M. Carpati, and E. C. Rackow.
1994.
Induction of endotoxin tolerance with monophosphoryl lipid A in peritonitis: importance of localized therapy.
J. Lab. Clin. Med.
123:89-93[Medline].
|
| 5.
|
Austin, O. M.,
H. P. Redmond,
W. G. Watson,
R. J. Cunney,
P. A. Grace, and D. Bouchier-Hayes.
1995.
The beneficial effects of immunostimulation in posttraumatic sepsis.
J. Surg. Res.
59:446-449[Medline].
|
| 6.
|
Baker, C. C.,
I. H. Chaudry,
H. O. Gaines, and A. E. Baue.
1983.
Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model.
J. Surg.
94:331-335.
|
| 7.
|
Berkman, N.,
M. John,
G. Roesems,
P. J. Jose,
P. J. Barnes, and K. F. Chung.
1995.
Inhibition of macrophage inflammatory protein-1 alpha expression by IL-10. Differential sensitivities in human blood monocytes and alveolar macrophages.
J. Immunol.
155:4412-4418[Abstract].
|
| 8.
|
Beutler, B.,
I. W. Milsark, and A. C. Cerami.
1985.
Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.
Science
229:869-871[Abstract/Free Full Text].
|
| 9.
|
Bevilacqua, M. P.,
J. S. Pober,
M. E. Wheeler,
R. S. Cotran, and M. A. Gimbrone, Jr.
1985.
Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines.
J. Clin. Invest.
76:2003-2011.
|
| 10.
|
Bone, R. C.
1993.
Gram-negative sepsis: a dilemma of modern medicine.
Clin. Microbiol. Rev.
6:57-68[Abstract/Free Full Text].
|
| 11.
|
Cross, A. K.,
V. Richardson,
S. A. Ali,
I. Palmer,
D. D. Taub, and R. C. Rees.
1997.
Migration responses of human monocytic cell lines to alpha- and beta-chemokines.
Cytokine
9:521-528[Medline].
|
| 12.
|
Dale, D. C.,
W. C. Liles,
W. R. Summer, and S. Nelson.
1995.
Granulocyte colony-stimulating factor role and relationships in infectious diseases.
J. Infect. Dis.
172:1061-1075[Medline].
|
| 13.
|
D'Andrea, A.,
M. Aste-Amezaga,
N. M. Valiante,
X. Ma,
M. Kubin, and G. Trinchieri.
1993.
Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells.
J. Exp. Med.
178:1041-1048[Abstract/Free Full Text].
|
| 14.
|
D'Andrea, A.,
M. Rengaraju,
N. M. Valiante,
J. Chehimi,
M. Kubin,
M. Aste,
S. H. Chan,
M. Kobayashi,
D. Young,
E. Nickbarg,
R. Chizzonite,
S. F. Wolf, and G. Trinchieri.
1992.
Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells.
J. Exp. Med.
176:1387-1398[Abstract/Free Full Text].
|
| 15.
|
Deutschman, C. S.,
B. A. Haber,
K. Andrejko,
D. E. Cressman,
R. Harrison,
E. Elenko, and R. Taub.
1996.
Increased expression of cytokine-induced neutrophil chemoattractant in septic rat liver.
Am. J. Physiol.
271:R593-R600[Abstract/Free Full Text].
|
| 16.
|
de Waal Malefyt, R.,
J. Abrams,
B. Bennett,
C. G. Figdor, and J. E. de Vries.
1991.
Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.
J. Exp. Med.
174:1209-1220[Abstract/Free Full Text].
|
| 17.
|
Doherty, D. E.,
G. P. Downey,
B. Schwab III,
E. Elson, and G. S. Worthen.
1994.
Lipolysaccharide-induced monocyte retention in the lung. Role of monocyte stiffness, actin assembly, and CD18-dependent adherence.
J. Immunol.
153:241-255[Abstract].
|
| 18.
|
Echtenacher, B.,
W. Falk,
D. N. Mannell, and P. H. Krammer.
1990.
Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis.
J. Immunol.
148:3762-3766.
|
| 19.
|
Essani, N. A.,
M. L. Bajt,
A. Farhood,
S. L. Vonderfecht, and H. Jaeschke.
1997.
Transcriptional activation of vascular cell adhesion molecule-1 gene in vivo and its role in the pathophysiology of neutrophil-induced liver injury in murine endotoxin shock.
J. Immunol.
158:5941-5948[Abstract].
|
| 20.
|
Essani, N. A.,
M. A. Fisher,
A. Farhood,
A. M. Manning,
C. W. Smith, and H. Jaeschke.
1995.
Cytokine-induced upregulation of hepatic intercellular adhesion molecule-1 messenger RNA expression and its role in the pathophysiology of murine endotoxin shock and acute liver failure.
Hepatology
21:1632-1639[Medline].
|
| 21.
|
Fischer, E.,
M. A. Marano,
K. J. Van Zee,
C. S. Rock,
A. S. Hawes,
W. A. Thompson,
L. DeForge,
J. S. Kenney,
D. G. Remick,
D. C. Bloedow,
S. F. Thompson, and L. L. Moldawer.
1992.
Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.
J. Clin. Invest.
89:1551-1557.
|
| 22.
|
Fultz, M. J.,
S. A. Barber,
C. W. Dieffenbach, and S. N. Vogel.
1993.
Induction of IFN-gamma in macrophages by lipopolysaccharide.
Int. Immunol.
5:1383-1392[Abstract/Free Full Text].
|
| 23.
|
Gazzinelli, R. T.,
I. Eltoum,
T. A. Wynn, and A. Sher.
1993.
Acute cerebral toxoplasmosis is induced by in vivo neutralization of TNF- and correlates with the down-regulated expression of inducible nitric oxide synthase and other markers of macrophage activation.
J. Immunol.
151:3672-3681[Abstract].
|
| 24.
|
Goebeler, M.,
J. Roth,
M. Kunz, and C. Sorg.
1993.
Expression of intercellular adhesion molecule-1 by murine macrophages is up-regulated during differentiation and inflammatory activation.
Immunobiology
188:159-171[Medline].
|
| 25.
|
Gustafson, G. L.,
M. J. Rhodes, and T. Hegel.
1995.
Monophosphoryl lipid A as a prophylactic for sepsis and septic shock, p. 567-579.
In
J. Levin, C. R. Alving, R. S. Munford, and H. Redl (ed.), Bacterial endotoxins: lipopolysaccharides from genes to therapy. Wiley-Liss, New York, N.Y.
|
| 26.
|
Hadjiminas, D. J.,
K. M. McMasters,
J. C. Peyton, and W. G. Cheadle.
1994.
Tissue tumor necrosis factor mRNA expression following cecal ligation and puncture or intraperitoneal injection of endotoxin.
J. Surg. Res.
56:549-555[Medline].
|
| 27.
|
Hadjiminas, D. J.,
K. M. McMasters,
J. C. Peyton,
M. D. Cook, and W. G. Cheadle.
1994.
Passive immunization against tumor necrosis factor and interleukin-1 fails to reduce lung neutrophil sequestration in chronic sepsis.
Shock
2:376-380[Medline].
|
| 28.
|
Heinzel, F. P.
1990.
The role of IFN- in the pathology of experimental endotoxemia.
J. Immunol.
145:2920-2924[Abstract].
|
| 29.
|
Heinzel, F. P.,
R. M. Rerko,
P. Ling,
J. Hakimi, and D. S. Schoenhaut.
1994.
Interleukin 12 is produced in vivo during endotoxemia and stimulates synthesis of gamma interferon.
Infect. Immun.
62:4244-4249[Abstract/Free Full Text].
|
| 30.
|
Henricson, B. E.,
W. R. Benjamin, and S. N. Vogel.
1990.
Differential cytokine induction by doses of lipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance.
Infect. Immun.
58:2429-2437[Abstract/Free Full Text].
|
| 31.
|
Henricson, B. E.,
C. L. Manthey,
P. Y. Perera,
T. A. Hamilton, and S. N. Vogel.
1993.
Dissociation of lipopolysaccharide (LPS)-inducible gene expression in murine macrophages pretreated with smooth LPS versus monophosphoryl lipid A.
Infect. Immun.
61:2325-2333[Abstract/Free Full Text].
|
| 32.
|
Hewett, J. A.,
A. E. Schultze,
S. VanCise, and R. A. Roth.
1992.
Neutrophil depletion protects against liver injury from bacterial endotoxin.
Lab. Invest.
66:347-361[Medline].
|
| 33.
|
Jaeschke, H.,
A. Farhood, and C. W. Smith.
1991.
Neutrophil-induced liver cell injury in endotoxin shock is a CD11b/CD18-dependent mechanism.
Am. J. Physiol.
261:G1051-1056[Abstract/Free Full Text].
|
| 34.
|
Kato, T.,
A. Murata,
H. Ishida,
H. Toda,
N. Tanaka,
H. Hayashida,
M. Monden, and N. Matsuura.
1995.
Interleukin 10 reduces mortality from severe peritonitis in mice.
Antimicrob. Agents Chemother.
39:1336-1340[Abstract].
|
| 35.
|
Li, S.,
S. X. Fan, and T. M. McKenna.
1996.
Role of nitric oxide in sepsis-induced hyporeactivity in isolated rat lungs.
Shock
5:122-129[Medline].
|
| 36.
|
Ling, P.,
M. K. Gately,
U. Gubler,
A. S. Stern,
P. Lin,
K. Hollfelder,
C. Su,
Y. C. Pan, and J. Hakimi.
1995.
Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity.
J. Immunol.
154:116-127[Abstract].
|
| 37.
|
MacMicking, J. D.,
C. Nathan,
G. Hom,
N. Chartrain,
D. S. Fletcher,
M. Trumbauer,
K. Stevens,
Q. W. Xie,
K. Sokol,
N. Hutchinson,
H. Chen, and J. S. Mudgett.
1995.
Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase.
Cell
81:641-650[Medline].
|
| 38.
|
Madonna, G. S.,
J. E. Peterson,
E. E. Ribi, and S. N. Vogel.
1986.
Early-phase endotoxin tolerance: induction by a detoxified lipid A derivative, monophosphoryl lipid A.
Infect. Immun.
52:6-11[Abstract/Free Full Text].
|
| 39.
|
Miles, R. H.,
T. P. Paxton,
D. J. Dries, and R. L. Gamelli.
1994.
Interferon-gamma increases mortality following cecal ligation and puncture.
J. Trauma
36:607-611[Medline].
|
| 40.
|
Okamura, H.,
H. Tsutsi,
T. Komatsu,
M. Yutsudo,
A. Hakura,
T. Tanimoto,
K. Torigoe,
T. Okura,
Y. Nukada,
K. Hattori,
K. Akita,
M. Namba,
F. Tanabe,
K. Konishi,
F. Fukuda, and M. Kurimoto.
1995.
Cloning of a new cytokine that induces IFN-gamma production by T cells.
Nature
378:88-91[Medline].
|
| 41.
|
O'Reilly, M.,
G. M. Silver,
D. G. Greenhalgh,
R. L. Gamelli,
J. H. Davis, and J. C. Hebert.
1992.
Treatment of intra-abdominal infection with granulocyte colony-stimulating factor.
J. Trauma
33:679-682[Medline].
|
| 42.
|
Peterson, V. M.,
J. J. Adamovicz,
T. B. Elliott,
M. M. Moore,
G. S. Madonna,
W. E. Jackson III,
G. D. Ledney, and W. C. Gause.
1994.
Gene expression of hematoregulatory cytokines is elevated endogenously after sublethal gamma irradiation and is differentially enhanced by therapeutic administration of biologic response modifiers.
J. Immunol.
153:2321-2330[Abstract].
|
| 43.
|
Remick, D.,
P. Manohar,
G. Bologos,
J. Rodriguez,
L. Moldawar, and G. Wollenberg.
1995.
Blockada of tumor necrosis factor reduces lipopolysaccharide, but not the lethality of cecal ligation and puncture.
Shock
4:89-95[Medline].
|
| 44.
|
Rudbach, J. A.,
K. R. Myers,
D. J. Rechtman, and J. T. Ulrich.
1994.
Prophylactic use of monophosphoryl lipid A in patients at risk for sepsis, p. 107-124.
In
J. Levin, S. J. H. van Deventer, T. van der Poll, and A. Sturk (ed.), Bacterial endotoxins. Basic science to anti-sepsis strategies. Wiley-Liss, Inc., New York, N.Y.
|
| 45.
|
Salkowski, C. A.,
G. Detore,
R. McNally,
N. van Rooijen, and S. N. Vogel.
1997.
Regulation of inducible nitric oxide synthase messenger RNA expression and nitric oxide production by lipopolysaccharide in vivo. The roles of macrophages, endogenous IFN-gamma, and TNF receptor-1-mediated signaling.
J. Immunol.
158:905-912[Abstract].
|
| 46.
|
Salkowski, C. A.,
G. R. Detore, and S. N. Vogel.
1997.
Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages.
Infect. Immun.
65:3239-3247[Abstract].
|
| 47.
|
Salkowski, C. A.,
K. Koplydowski,
A. Franks,
M. Falk, and S. N. Vogel.
1997.
In vivo chemokine mRNA expression during endotoxemia, peritonitis and tolerance, abstr. S5.
In
Abstracts of The Society for Leukocyte Biology 32nd Annual Meeting. Society for Leukocyte Biology, Baltimore, Md.
|
| 48.
|
Salkowski, C. A.,
R. Neta,
T. A. Wynn,
G. Strassmann,
N. van Rooijen, and S. N. Vogel.
1995.
Effect of liposome-mediated macrophage depletion on LPS-induced cytokine gene expression and radioprotection.
J. Immunol.
155:3168-3179[Abstract].
|
| 49.
| Salkowski, C. A., and S. N. Vogel.
Unpublished data.
|
| 50.
|
Savage, C. O.,
C. J. Brooks,
D. Adu,
G. Richards, and A. J. Howie.
1997.
Cell adhesion molecule expression within human glomerular and kidney organ culture.
J. Pathol.
181:111-115[Medline].
|
| 51.
|
Schmal, H.,
T. P. Shanley,
M. L. Jones,
H. P. Friedl, and P. A. Ward.
1996.
Role for macrophage inflammatory protein-2 in lipopolysaccharide-induced lung injury in rats.
J. Immunol.
156:1963-1972[Abstract].
|
| 52.
|
Sivo, J.,
C. A. Salkowski,
A. D. Politis, and S. N. Vogel.
1994.
Differential regulation of LPS-induced IL-1 and IL-1 receptor antagonist mRNA by IFN and IFN in murine peritoneal macrophages.
J. Endotoxin Res.
1:30-37.
|
| 53.
|
Standiford, T. J.,
S. L. Kunkel,
N. W. Lukacs,
M. J. Greenberger,
J. M. Danforth,
R. G. Kunkel, and R. M. Strieter.
1995.
Macrophage inflammatory protein-1 mediates lung leukocyte recruitment, lung capillary leak, and early mortality in murine endotoxemia.
J. Immunol.
155:1515-1524[Abstract].
|
| 54.
|
Stephens, K. E.,
A. Ishizaka,
J. W. Larrick, and T. A. Raffin.
1988.
Tumor necrosis factor causes increased pulmonary permeability and edema. Comparison to septic acute lung injury.
Am. Rev. Respir. Dis.
137:1364-1370[Medline].
|
| 55.
|
Trepicchio, W. L.,
M. Bozza,
G. Pedneault, and A. J. Dorner.
1996.
Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production.
J. Immunol.
157:3627-3634[Abstract].
|
| 56.
|
Ulich, T. R.,
K. Guo, and J. del Castillo.
1989.
Endotoxin-induced cytokine gene expression in vivo. I. Expression of tumor necrosis factor mRNA in visceral organs under physiologic conditions and during endotoxemia.
Am. J. Pathol.
134:11-14[Abstract].
|
| 57.
|
Ulich, T. R.,
S. C. Howard,
D. G. Remick,
A. Wittwer,
E. S. Yi,
S. Yin,
K. Guo,
J. K. Welply, and J. H. Williams.
1995.
Intratracheal administration of endotoxin and cytokines. VI. Antiserum to CINC inhibits acute inflammation.
Am. J. Physiol.
268:L245-250[Abstract/Free Full Text].
|
| 58.
|
van der Poll, T.,
A. Marchant,
W. A. Buurman,
L. Berman,
C. V. Keogh,
D. D. Lazarus,
L. Nguyen,
M. Goldman,
L. L. Moldawer, and S. F. Lowry.
1995.
Endogenous IL-10 protects mice from death during septic peritonitis.
J. Immunol.
155:5397-5401[Abstract].
|
| 59.
|
VanOtteren, G. M.,
R. M. Strieter,
S. L. Kunkel,
R. Paine III,
M. J. Greenberger,
J. M. Danforth,
M. D. Burdick, and T. J. Standiford.
1995.
Compartmentalized expression of RANTES in a murine model of endotoxemia.
J. Immunol.
154:1900-1908[Abstract].
|
| 60.
|
Villa, P.,
M. Demitri,
C. Meazza,
M. Sironi,
P. Gnocchi, and P. Ghezzi.
1996.
Effects of methyl palmitate on cytokine release, liver injury and survival in mice with sepsis.
Eur. Cytokine Network
7:765-769[Medline].
|
| 61.
|
Villa, P.,
M. Meassa,
M. Sironi,
M. Bianchi,
P. Ulrich,
G. Botchkina,
K. J. Tracey, and P. Ghezzi.
1997.
Protection against lethal polymicrobial sepsis by CNI-1493, an inhibitor of pro-inflammatory cytokine synthesis.
J. Endotoxin Res.
4:197-204.
[Abstract/Free Full Text] |
| 62.
|
Villa, P.,
G. Sartor,
M. Angelini,
M. Sironi,
M. Conni,
P. Gnocchi,
A. M. Isetta,
G. Grau,
W. Burrman,
L. J. van Tits, and P. Ghezzi.
1995.
Pattern of cytokines and pharmacomodulation in sepsis induced by cecal ligation and puncture compared with that induced by endotoxin.
Clin. Diagn. Lab. Immunol.
2:549-553[Abstract].
|
| 63.
|
Walley, K. R.,
N. W. Lukacs,
T. J. Standiford,
R. M. Strieter, and S. L. Kunkel.
1996.
Balance of inflammatory cytokines related to severity and mortality of murine sepsis.
Infect. Immun.
64:4733-4738[Abstract].
|
| 64.
|
Walley, K. R.,
N. W. Lukacs,
T. J. Standiford,
R. M. Strieter, and S. L. Kunkel.
1997.
Elevated levels of macrophage inflammatory protein 2 in severe murine peritonitis increase neutrophil recruitment and mortality.
Infect. Immun.
65:3847-3851[Abstract].
|
| 65.
|
Wang, J. M.,
Z. G. Chen,
S. Colella,
M. A. Bonilla,
K. Welte,
C. Bordignon, and A. Mantovani.
1988.
Chemotactic activity of recombinant human granulocyte colony-stimulating factor.
Blood
72:1456-1460[Abstract/Free Full Text].
|
| 66.
|
Wickel, D. J.,
W. G. Cheadle,
M. A. Mercer-Jones, and R. N. Garrison.
1997.
Poor outcome from peritonitis is caused by disease acuity and organ failure, not recurrent peritoneal infection.
Ann. Surg.
225:744-753[Medline].
|
| 67.
|
Wilson, M. A.,
M. C. Chou,
D. A. Spain,
P. J. Downard,
Q. Qian,
W. G. Cheadle, and R. N. Garrison.
1996.
Fluid resuscitation attenuates early cytokine mRNA expression after peritonitis.
J. Trauma
41:622-627[Medline].
|
| 68.
|
Witthaut, R.,
A. Farhood,
C. W. Smith, and H. Jaeschke.
1994.
Complement and tumor necrosis factor- contribute to Mac-1 (CD11b/CD18) up-regulation and systemic neutrophil activation during endotoxemia in vivo.
J. Leukocyte Biol.
55:105-111[Abstract].
|
| 69.
|
Wuyts, A.,
A. Haelens,
P. Proost,
J. P. Lenaerts,
R. Conings,
G. Opdenakker, and J. Van Damme.
1996.
Identification of mouse granulocyte chemotactic protein-2 from fibroblasts and epithelial cells. Functional comparison with natural KC and macrophage inflammatory protein-2.
J. Immunol.
157:1736-1743[Abstract].
|
| 70.
|
Wynn, T. A.,
I. Eltoum,
A. W. Cheever,
F. A. Lewis,
W. C. Gause, and A. Sher.
1993.
Analysis of cytokine mRNA expression during primary granuloma formation induced by eggs of Schistosoma mansoni.
J. Immunol.
151:1430-1440[Abstract].
|
| 71.
|
Wysocka, M.,
M. Kubin,
L. Q. Vieira,
L. Ozmen,
G. Garotta,
P. Scott, and G. Trinchieri.
1995.
Interleukin-12 is required for interferon- production and lethality in lipopolysaccharide-induced shock in mice.
Eur. J. Immunol.
25:672-676[Medline].
|
| 72.
|
Yao, Z.,
P. A. Foster, and G. J. Gross.
1994.
Monophosphoryl lipid A protects against endotoxic shock via inhibiting neutrophil infiltration and preventing disseminated intravascular coagulation.
Circ. Shock
43:107-114[Medline].
|
Infect Immun, August 1998, p. 3569-3578, Vol. 66, No. 8
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Shea-Donohue, T., Thomas, K., Cody, M. J., Aiping Zhao, , DeTolla, L. J., Kopydlowski, K. M., Fukata, M., Lira, S. A., Vogel, S. N.
(2008). Mice deficient in the CXCR2 ligand, CXCL1 (KC/GRO-{alpha}), exhibit increased susceptibility to dextran sodium sulfate (DSS)-induced colitis. Innate Immunity
14: 117-124
[Abstract]
-
Potts, B. E., Chapes, S. K.
(2008). Functions of C2D macrophage cells after adoptive transfer. J. Leukoc. Biol.
83: 602-609
[Abstract]
[Full Text]
-
Hegde, A., Zhang, H., Moochhala, S. M., Bhatia, M.
(2007). Neurokinin-1 receptor antagonist treatment protects mice against lung injury in polymicrobial sepsis. J. Leukoc. Biol.
82: 678-685
[Abstract]
[Full Text]
-
Thomas, K. E., Galligan, C. L., Newman, R. D., Fish, E. N., Vogel, S. N.
(2006). Contribution of Interferon-beta to the Murine Macrophage Response to the Toll-like Receptor 4 Agonist, Lipopolysaccharide. J. Biol. Chem.
281: 31119-31130
[Abstract]
[Full Text]
-
Cook, C. H., Trgovcich, J., Zimmerman, P. D., Zhang, Y., Sedmak, D. D.
(2006). Lipopolysaccharide, Tumor Necrosis Factor Alpha, or Interleukin-1{beta} Triggers Reactivation of Latent Cytomegalovirus in Immunocompetent Mice.. J. Virol.
80: 9151-9158
[Abstract]
[Full Text]
-
Osuchowski, M. F., Welch, K., Siddiqui, J., Remick, D. G.
(2006). Circulating Cytokine/Inhibitor Profiles Reshape the Understanding of the SIRS/CARS Continuum in Sepsis and Predict Mortality. J. Immunol.
177: 1967-1974
[Abstract]
[Full Text]
-
Thomas, K. E., Sapone, A., Fas